FDA Approves RYZUMVI — Oyster Point Pharma, Inc.

On September 25, Oyster Point Pharma announced FDA approval of RYZUMVI (phentolamine mesylate) ophthalmic solution for the treatment of surgically induced astigmatism during cataract surgery, a development that positions the company to capitalize on the rapid post-market growth of premium cataract lens technology. This milestone acquisition establishes a critical new treatment option to address a leading complication in a swelling global market, creating a significant opportunity for commercial scale-up and recurring peak sales forecasts.